Cargando…
Anti-tumor antibody isotype response can be modified with locally administered immunoadjuvants
In situ vaccination with immunostimulatory compounds is a demonstrated means to treat tumors preclinically. While these therapeutic effects have been attributed to the actions of T cells or innate immune activation, characterisation of the humoral immune response is seldom performed. This study aims...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238356/ https://www.ncbi.nlm.nih.gov/pubmed/36417163 http://dx.doi.org/10.1007/s13346-022-01258-8 |